Gene Therapy Could End Transfusions for Blood Disorder Patients
Credit: "montuno" on Flickr (https://www.flickr.com/photos/montuno/2285013430/) [CC BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0)], via Wikimedia Commons
Gene therapy for transfusion-dependent thalassemia, an inherited blood disorder, produced positive outcomes in an interim analysis of two international Phase 1/2 clinical trials, according to the results published in New England Journal of Medicine. Out of 22 patients aged 12 – 35 years, 15 patients achieved transfusion-free status, while others needed transfusions less often.
People with thalassemia cannot make enough hemoglobin in their red blood cells, which interferes with oxygen getting to all parts of the body. Those with the most severe type of the disease require red blood cell transfusions every month for survival. Frequent transfusions, however, can cause serious complications due to iron toxicity and viral infections.
"We saw remarkable outcomes using LentiGlobin gene therapy, with most patients no longer needing monthly transfusions,” said leading author Alexis Thompson, MD, Head of Hematology and Director of the Comprehensive Thalassemia Program at Ann & Robert H. Lurie Children’s Hospital of Chicago, as well as Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “These study results exceeded our expectations with clinical benefit for nearly all patients, and suggest that gene therapy may be an effective treatment for thalassemia in the future.”
The studies used the patient’s own stem cells that were treated in the lab with a modified virus to replace the gene that is defective in thalassemia. The patient needed to undergo chemotherapy before the new cells could be infused. Patients typically reached peak production of hemoglobin in nine to 12 months after infusion. They were then monitored for 15 – 42 months after receiving the new cells. Treatment-related adverse events were typical of autologous stem cell transplantation. No safety issue could be attributed to gene therapy in either of the studies. Researchers plan to continue follow-up with all patients for 15 years.
“While these gene therapy trials were the largest for thalassemia to date, we need to evaluate effectiveness in a much larger population,” said Thompson, who also is the President of the American Society of Hematology (ASH). “Since we saw such positive results, we are now enrolling patients as young as 5 years old on a Phase 3 trial of gene therapy for transfusion-dependent thalassemia.”
This article has been republished from materials provided by Lurie Children's Hospital. Note: material may have been edited for length and content. For further information, please contact the cited source.
Reference: Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., … Cavazzana, M. (2018). Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. New England Journal of Medicine, 378(16), 1479–1493. https://doi.org/10.1056/NEJMoa1705342
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.